{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:42Z","timestamp":1784408862970,"version":"3.55.0"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Generalized pustular psoriasis (GPP) is a severe, relapsing skin disorder characterized by widespread erythema and sterile pustules. Classical systemic therapies often yield suboptimal results. Xeligekimab is a novel, fully human anti-interleukin-17A (anti-IL-17A) monoclonal antibody recently approved in China for plaque psoriasis. Its efficacy in GPP has not been previously reported. This report presents two cases of refractory GPP successfully treated with xeligekimab. Both patients- a 25-year-old male and a 70-year-old male had long-standing GPP that was unresponsive to conventional systemic therapies including acitretin and methotrexate. After receiving a single 200 mg dose of xeligekimab, both patients exhibited rapid and significant clinical improvement within 3 to 4 days. Remarkably, one patient remained in remission at the 3-month follow-up after only one injection. This is the first report to suggest that xeligekimab is a potent and promising therapeutic option for inducing rapid and sustained remission in patients with GPP.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1748050","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:47:53Z","timestamp":1781243273000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Successful treatment of refractory generalized pustular psoriasis with xeligekimab: a report of two cases"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiao","family":"Zang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Shandong Provincial Hospital of Dermatology","place":["Jinan, China"]},{"name":"Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shandong Provincial Hospital of Dermatology","place":["Jinan, China"]},{"name":"Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shandong Provincial Hospital of Dermatology","place":["Jinan, China"]},{"name":"Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shandong Provincial Hospital of Dermatology","place":["Jinan, China"]},{"name":"Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shandong Provincial Hospital of Dermatology","place":["Jinan, China"]},{"name":"Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1682502","article-title":"Review of treatments for generalized pustular psoriasis","volume":"32","author":"Kearns","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1462158","article-title":"Biologics for generalized pustular psoriasis: a systematic review and single-arm meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17337","article-title":"Spesolimab improved pustules on the palms and soles that were refractory to tumor necrosis factor inhibitors and interleukin-17 inhibitors in a patient with generalized pustular psoriasis: a case report","volume":"51","author":"Suzuki","year":"2024","journal-title":"J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S323239","article-title":"Infliximab in combination with low-dose acitretin in generalized pustular psoriasis: a report of two cases and review of the literature","volume":"15","author":"Ko\u0142t-Kami\u0144ska","year":"2021","journal-title":"Biologics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2089327","article-title":"Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review","volume":"33","author":"Du","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2019.55.9.3020159","article-title":"The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis","volume":"55","author":"Plachouri","year":"2019","journal-title":"Drugs Today (Barc)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18069","article-title":"Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis","volume":"36","author":"Avallone","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","article-title":"Treatment options and goals for patients with generalized pustular psoriasis","volume":"23","author":"Krueger","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40265-024-02125-1","article-title":"Xeligekimab: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1748050\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:48:06Z","timestamp":1781243286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1748050\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":9,"alternative-id":["10.3389\/fimmu.2026.1748050"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1748050","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1748050"}}